GlobeNewswire• August 15, 2018
GERMANTOWN, Md., Aug. 15, 2018 (GLOBE NEWSWIRE) — Orgenesis Inc. (ORGS) (“Orgenesis” or “the Company”), a manufacturer, service provider, and developer of advanced cell therapies, today announced that Dr. Ohad Karnieli, Ph.D., MBA, Chief Executive Officer and Co-Founder of Atvio Biotech Ltd., which is wholly-owned by Orgenesis’ Masthercell Global subsidiary, will be presenting at the Bioprocessing Summit within Cambridge Healthtech Institute’s (CHI) 5thAnnual Cell Therapy Manufacturing segment, being held August 15th to 16th in Boston, Massachusetts. Dr. Karnieli will speak during the “Automation, Closed Systems and Biosensors” session in a presentation entitled, “Next-Generation CAR T Manufacturing, Bedside Automated Manufacturing, No Longer a Dream.” Dr. Karnieli will also open the “Commercialization Strategies” and “Scale-up and Manufacture” segments in his role as Chairman of the Process and Product Development Subcommittee for the International Society of Cellular Therapies.
CHI’s Cell Therapy Manufacturing conference takes an in-depth look at the challenges faced when manufacturing autologous and allogeneic cell therapies at scale. Dr. Karnieli will focus on new available technologies and future trends regarding CAR T manufacturing. He will also be presenting a case study of a CAR T therapy, end-to-end automated process called ADVA.
Location: The Sheraton Boston
Room: Back Bay C
Date & Time: Wednesday, August 15, at 2:20 p.m., ET
About Atvio Biotechnology
Atvio Biotech Ltd., a wholly owned subsidiary of Masthercell Global Inc., is a cell therapy process innovation center with a focus on cGMP cell and gene manufacturing, virus manufacturing, process development, custom automation and translation of cell therapies from lab to market.
Orgenesis Inc is a vertically-integrated biopharmaceutical company with expertise and unique experience in cell therapy development and support services. Through its Israeli subsidiary, Orgenesis Ltd., Orgenesis is developing technology designed to successfully reprogram human liver cells into glucose-responsive, fully functional, Insulin Producing Cells (IPCs). Orgenesis believes that converting the diabetic patient’s own tissue into insulin-producing cells has the potential to overcome the significant issues of donor shortage, cost and exposure to chronic immunosuppressive therapy associated with islet cell transplantation. Through its subsidiary Masthercell Global Inc., a global contract development and manufacturing organization (CDMO), Orgenesis is able to deliver optimized process industrialization capacities to cell therapy organizations and speed up the arrival of their therapies onto the market. From technology selection to business modeling, GMP manufacturing, process development, and quality management, Masthercell’s teams are fully committed to helping their clients fulfill their objective of providing sustainable and affordable therapies to their patients. Masthercell operates in a validated and flexible facility located in the strategic center of Europe within the Walloon healthcare cluster, Biowin. This integrated approach supports the Company’s business philosophy of bringing to market significant life-improving medical treatments. For more information, visit www.orgenesis.com.